These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
746 related articles for article (PubMed ID: 32728218)
21. mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma. Wang Y; Zhang L; Xu Z; Miao L; Huang L Mol Ther; 2018 Feb; 26(2):420-434. PubMed ID: 29249397 [TBL] [Abstract][Full Text] [Related]
22. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression. Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262 [TBL] [Abstract][Full Text] [Related]
23. A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKβ-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma. Koch EAT; Schaft N; Kummer M; Berking C; Schuler G; Hasumi K; Dörrie J; Schuler-Thurner B Front Immunol; 2022; 13():785231. PubMed ID: 35185883 [TBL] [Abstract][Full Text] [Related]
24. Immune Checkpoint Therapy in Melanoma. Callahan MK Cancer J; 2016; 22(2):73-80. PubMed ID: 27111901 [TBL] [Abstract][Full Text] [Related]
25. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. Germeau C; Ma W; Schiavetti F; Lurquin C; Henry E; Vigneron N; Brasseur F; Lethé B; De Plaen E; Velu T; Boon T; Coulie PG J Exp Med; 2005 Jan; 201(2):241-8. PubMed ID: 15657293 [TBL] [Abstract][Full Text] [Related]
26. Melanoma cancer vaccines and anti-tumor T cell responses. Vujanovic L; Butterfield LH J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270 [TBL] [Abstract][Full Text] [Related]
27. Rapid and Continued T-Cell Differentiation into Long-term Effector and Memory Stem Cells in Vaccinated Melanoma Patients. Gannon PO; Baumgaertner P; Huber A; Iancu EM; Cagnon L; Abed Maillard S; Maby-El Hajjami H; Speiser DE; Rufer N Clin Cancer Res; 2017 Jul; 23(13):3285-3296. PubMed ID: 27872103 [No Abstract] [Full Text] [Related]
28. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Davila E; Kennedy R; Celis E Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660 [TBL] [Abstract][Full Text] [Related]
29. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810 [TBL] [Abstract][Full Text] [Related]
30. Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses. Santos PM; Adamik J; Howes TR; Du S; Vujanovic L; Warren S; Gambotto A; Kirkwood JM; Butterfield LH J Exp Med; 2020 Jul; 217(7):. PubMed ID: 32369107 [TBL] [Abstract][Full Text] [Related]
31. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262 [TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of a potential checkpoint blockade vaccine for canine melanoma. Kurupati RK; Zhou X; Xiang Z; Keller LH; Ertl HCJ Cancer Immunol Immunother; 2018 Oct; 67(10):1533-1544. PubMed ID: 30051333 [TBL] [Abstract][Full Text] [Related]
33. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. Berard F; Blanco P; Davoust J; Neidhart-Berard EM; Nouri-Shirazi M; Taquet N; Rimoldi D; Cerottini JC; Banchereau J; Palucka AK J Exp Med; 2000 Dec; 192(11):1535-44. PubMed ID: 11104796 [TBL] [Abstract][Full Text] [Related]
34. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine. Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512 [TBL] [Abstract][Full Text] [Related]
35. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391 [TBL] [Abstract][Full Text] [Related]
36. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339 [TBL] [Abstract][Full Text] [Related]
37. Vaccines and melanoma. Ott PA; Fritsch EF; Wu CJ; Dranoff G Hematol Oncol Clin North Am; 2014 Jun; 28(3):559-69. PubMed ID: 24880947 [TBL] [Abstract][Full Text] [Related]
38. Dissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants. Pampena MB; Cartar HC; Cueto GR; Levy EM; Blanco PA; Barrio MM; Mordoh J Front Immunol; 2018; 9():2531. PubMed ID: 30450100 [TBL] [Abstract][Full Text] [Related]
39. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Cabrita R; Lauss M; Sanna A; Donia M; Skaarup Larsen M; Mitra S; Johansson I; Phung B; Harbst K; Vallon-Christersson J; van Schoiack A; Lövgren K; Warren S; Jirström K; Olsson H; Pietras K; Ingvar C; Isaksson K; Schadendorf D; Schmidt H; Bastholt L; Carneiro A; Wargo JA; Svane IM; Jönsson G Nature; 2020 Jan; 577(7791):561-565. PubMed ID: 31942071 [TBL] [Abstract][Full Text] [Related]
40. Melanoma vaccines: the paradox of T cell activation without clinical response. Nielsen MB; Marincola FM Cancer Chemother Pharmacol; 2000; 46 Suppl():S62-6. PubMed ID: 10950150 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]